近年来,由于达美康(GZ)等药物的问世,口服降糖药治疗粮尿病(DM)和延缓其血管并发症的发生有了新的进展。磺脲类口服降糖药为胰岛素(INS)促泌剂。第2代磺脲药可分为以下2种: 1、优降糖:对INS释放虽有强烈的影响,但其作用是促进后期的,延迟的释放,故偶可引起严重的低血糖反应,甚至造成死亡。 2、达美康(GZ)、吡磺环已脲、“罗氏”克尿糖:可促进胰岛β细胞在注射葡萄糖后立即分泌胰岛素,故其效果更符合生理性。而对INS的晚期分泌并无明显的增加,因此,可避免低血糖的发生及食欲增加,对 In recent years, due to the advent of drugs such as Gramelin (GZ), oral hypoglycemic agents to treat diabetes mellitus (DM) and delay the occurrence of vascular complications have made new progress. Sulfonylurea oral hypoglycemic agents for insulin (INS) secretagogues. The second generation of sulfonylureas can be divided into the following two kinds: 1, glyburide: Although INS release has a strong impact, but its role is to promote the late, delayed release, so even can cause severe hypoglycemia, Even cause death. 2, up to the United States and health (GZ), sulfonylurea urea, “Roche” urine: can promote pancreatic β-cell insulin secretion immediately after injection of glucose, so the effect is more in line with the physiological. While the late secretion of INS did not significantly increase, therefore, to avoid the occurrence of hypoglycemia and increased appetite, right